Current understandings and clinical translation of nanomedicines for breast cancer therapy

Yike Jiang, Ziyi Jiang, Mingzhe Wang, Lan Ma

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Breast cancer is one of the most frequently diagnosed cancers that is threatening women's life. Current clinical treatment regimens for breast cancer often involve neoadjuvant and adjuvant systemic therapies, which somewhat are associated with unfavorable features. Also, the heterogeneous nature of breast cancers requires precision medicine that cannot be fulfilled by a single type of systemically administered drug. Taking advantage of the nanocarriers, nanomedicines emerge as promising therapeutic agents for breast cancer that could resolve the defects of drugs and achieve precise drug delivery to almost all sites of primary and metastatic breast tumors (e.g. tumor vasculature, tumor stroma components, breast cancer cells, and some immune cells). Seven nanomedicines as represented by Doxil® have been approved for breast cancer clinical treatment so far. More nanomedicines including both non-targeting and active targeting nanomedicines are being evaluated in the clinical trials. However, we have to realize that the translation of nanomedicines, particularly the active targeting nanomedicines is not as successful as people have expected. This review provides a comprehensive landscape of the nanomedicines for breast cancer treatment, from laboratory investigations to clinical applications. We also highlight the key advances in the understanding of the biological fate and the targeting strategies of breast cancer nanomedicine and the implications to clinical translation.

Original languageEnglish (US)
Article number114034
JournalAdvanced Drug Delivery Reviews
Volume180
DOIs
StatePublished - Jan 2022

Keywords

  • Breast cancer
  • Clinical translation
  • Drug delivery
  • Nanomedicine
  • Non-viral nanocarriers

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Current understandings and clinical translation of nanomedicines for breast cancer therapy'. Together they form a unique fingerprint.

Cite this